PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: PF-04383119 (tanezumab)
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 83
- Registration Number
- NCT00669409
- Locations
- π―π΅
Medical Corporation Yamamoto Kinenkai Yamamoto Kinen Hospital, Yokohama-shi, Kanagawa-ken, Japan
π―π΅Nippon Kokan Clinic, Kawasaki, Kanagawa, Japan
π―π΅FuruKawabashi Hospital, Minato-ku, Tokyo, Japan
Bioequivalence Study Of Verapamil
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00668967
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
- Conditions
- Unresectable or Metastatic Colorectal Cancer
- Interventions
- Drug: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT00668863
- Locations
- π―π΅
Pfizer Investigational Site, Minoh/Osaka, Japan
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 901
- Registration Number
- NCT00667810
- Locations
- πΊπΈ
Clinical Trials, Inc., Little Rock, Arkansas, United States
πΊπΈCenter for Healthy Aging, Greenwich, Connecticut, United States
πΊπΈChase Medical Research, LLC, Waterbury, Connecticut, United States
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1004
- Registration Number
- NCT00666276
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
- Conditions
- Dental Pain
- Interventions
- Drug: ARRY-371797, p38 inhibitor; oralDrug: Celecoxib, COX-2 inhibitor; oralDrug: Placebo; oral
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00663767
- Locations
- πΊπΈ
PPD Phase I Clinic, Austin, Texas, United States
πΊπΈLifetree Clinical Research, Salt Lake City, Utah, United States
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00663026
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Drug: Placebo for Fragmin/ Dalteparin Sodium
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 276
- Registration Number
- NCT00662831
- Locations
- π¬π§
Pfizer Investigational Site, Peterborough, United Kingdom
Study Of Sunitinib With Capecitabine In Breast Cancer
- Conditions
- Advanced/Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 63
- Registration Number
- NCT00662025
- Locations
- π―π΅
Pfizer Investigational Site, Osaka, Japan
Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 273
- Registration Number
- NCT00663052
- Locations
- πΉπ
Pfizer Investigational Site, Bangkok, Thailand